TrumpLyftAlles | 3 points
The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism (China 2013) Decreases blood sugar and cholesterol?![-] MermaidLeggs | 1 points
It’s crazy how many uses they are discovering for this one drug.
I’m currently using it for rosacea.
Obviously parasites - human and animal
Possibly COVID-19
Hyperglycemia
High cholesterol
What else am I missing?
[-] Haitchpeasauce | 2 points
Just last night I saw a paper from 2016 studying Ivermectin's potential benefit against breast cancer: Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer
Basically it enables malfunctioning (cancer) cells to self-terminate.
If I recall correctly, the Akt/mTOR signalling pathway is also inhibited by ketogenesis and there is research into the effect of keto diet on diabetes, cancer etc. mTOR is associated with aging and cellular senescence.
[-] MermaidLeggs | 2 points
Oh that reminded me of a study I read showing positive results in ovarian cancer I think...
[-] Ok-Film-9049 | 1 points
I read the research on cancer and IVM. it appeared that tumours, in some people, become resistant to chemo but the IVM added to the therapy had a dramatic impact on tumour reduction.
I was disappointed that no one really followed this up in terms of clinical adoption, and was left feeling that had the drug had been patented it might have been very different.
[-] TrumpLyftAlles | 2 points | Sep 29 2020 00:34:32
Mouse study.
Abstract Farnesoid X receptor (FXR) has important roles in maintaining bile acid and cholesterol homeostasis. Here we report that the antiparasitic drug ivermectin is a ligand for nuclear FXR. We identify ivermectin using a high-throughput compound library screening and show that it induces the transcriptional activity of the FXR with distinctive properties in modulating coregulator recruitment. The crystal structure of ivermectin complexed with the ligand-binding domain of FXR reveals a unique binding mode of ivermectin in the FXR ligand-binding pocket, including the highly dynamic AF-2 helix and an expanded ligand-binding pocket. Treatment of wild-type mice, but not of FXR-null mice, with ivermectin decreases serum glucose and cholesterol levels, suggesting that ivermectin regulates metabolism through FXR. Our results establish FXR as the first mammalian protein targeted by ivermectin with high selectivity. Considering that ivermectin is a widely used clinical drug, our findings reveal a safe template for the design of novel FXR ligands.
permalink